Retrospective studies have correlated BRCA1 and BRCA2 mutations, higher tumor mutation burden and infiltration by T cells with improved survival in HGSOC,36, 37 and BRCA2 mutations were found to be enriched among long‐term responders to PARP inhibition.38 The gene discussed is BRCA2; the disease is neoplasm.